|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FLNB |
Gene summary for FLNB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FLNB | Gene ID | 2317 |
| Gene name | filamin B | |
| Gene Alias | ABP-278 | |
| Cytomap | 3p14.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | O75369 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2317 | FLNB | GSM4909281 | Human | Breast | IDC | 2.52e-14 | 4.93e-01 | 0.21 |
| 2317 | FLNB | GSM4909296 | Human | Breast | IDC | 5.82e-03 | -1.20e-01 | 0.1524 |
| 2317 | FLNB | GSM4909297 | Human | Breast | IDC | 2.00e-02 | -9.20e-02 | 0.1517 |
| 2317 | FLNB | GSM4909298 | Human | Breast | IDC | 1.72e-09 | 3.35e-01 | 0.1551 |
| 2317 | FLNB | GSM4909301 | Human | Breast | IDC | 2.85e-27 | 7.38e-01 | 0.1577 |
| 2317 | FLNB | GSM4909304 | Human | Breast | IDC | 1.03e-14 | 5.06e-01 | 0.1636 |
| 2317 | FLNB | GSM4909311 | Human | Breast | IDC | 1.84e-19 | 1.27e-01 | 0.1534 |
| 2317 | FLNB | GSM4909312 | Human | Breast | IDC | 4.41e-02 | -1.42e-02 | 0.1552 |
| 2317 | FLNB | GSM4909319 | Human | Breast | IDC | 7.46e-16 | -7.51e-02 | 0.1563 |
| 2317 | FLNB | GSM4909320 | Human | Breast | IDC | 1.37e-06 | 3.32e-01 | 0.1575 |
| 2317 | FLNB | GSM4909321 | Human | Breast | IDC | 1.33e-09 | 1.60e-01 | 0.1559 |
| 2317 | FLNB | brca3 | Human | Breast | Precancer | 3.75e-04 | 2.39e-01 | -0.0263 |
| 2317 | FLNB | M1 | Human | Breast | IDC | 1.27e-14 | 6.30e-01 | 0.1577 |
| 2317 | FLNB | NCCBC14 | Human | Breast | DCIS | 1.09e-05 | -7.28e-02 | 0.2021 |
| 2317 | FLNB | NCCBC2 | Human | Breast | DCIS | 7.91e-12 | 6.93e-01 | 0.1554 |
| 2317 | FLNB | NCCBC5 | Human | Breast | DCIS | 3.00e-06 | -1.09e-01 | 0.2046 |
| 2317 | FLNB | P1 | Human | Breast | IDC | 3.17e-08 | 1.52e-01 | 0.1527 |
| 2317 | FLNB | P3 | Human | Breast | IDC | 1.00e-09 | 8.24e-01 | 0.1542 |
| 2317 | FLNB | DCIS2 | Human | Breast | DCIS | 1.69e-40 | 6.47e-02 | 0.0085 |
| 2317 | FLNB | CCI_1 | Human | Cervix | CC | 4.47e-12 | 1.38e+00 | 0.528 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00085445 | Breast | Precancer | epidermis development | 35/1080 | 324/18723 | 2.71e-04 | 3.96e-03 | 35 |
| GO:00099136 | Breast | Precancer | epidermal cell differentiation | 23/1080 | 202/18723 | 1.43e-03 | 1.50e-02 | 23 |
| GO:00302163 | Breast | Precancer | keratinocyte differentiation | 17/1080 | 139/18723 | 2.71e-03 | 2.39e-02 | 17 |
| GO:00605374 | Breast | Precancer | muscle tissue development | 37/1080 | 403/18723 | 3.60e-03 | 2.98e-02 | 37 |
| GO:00020649 | Breast | Precancer | epithelial cell development | 23/1080 | 220/18723 | 4.28e-03 | 3.35e-02 | 23 |
| GO:00147063 | Breast | Precancer | striated muscle tissue development | 35/1080 | 384/18723 | 5.10e-03 | 3.83e-02 | 35 |
| GO:006053711 | Breast | IDC | muscle tissue development | 50/1434 | 403/18723 | 4.91e-04 | 6.45e-03 | 50 |
| GO:000854412 | Breast | IDC | epidermis development | 41/1434 | 324/18723 | 1.03e-03 | 1.14e-02 | 41 |
| GO:000991312 | Breast | IDC | epidermal cell differentiation | 28/1434 | 202/18723 | 1.62e-03 | 1.60e-02 | 28 |
| GO:00147061 | Breast | IDC | striated muscle tissue development | 46/1434 | 384/18723 | 1.67e-03 | 1.63e-02 | 46 |
| GO:00302161 | Breast | IDC | keratinocyte differentiation | 21/1434 | 139/18723 | 2.06e-03 | 1.95e-02 | 21 |
| GO:00343414 | Breast | IDC | response to interferon-gamma | 21/1434 | 141/18723 | 2.46e-03 | 2.22e-02 | 21 |
| GO:00435883 | Breast | IDC | skin development | 33/1434 | 263/18723 | 3.46e-03 | 2.87e-02 | 33 |
| GO:000206414 | Breast | IDC | epithelial cell development | 28/1434 | 220/18723 | 5.53e-03 | 4.05e-02 | 28 |
| GO:00075172 | Breast | IDC | muscle organ development | 38/1434 | 327/18723 | 6.63e-03 | 4.62e-02 | 38 |
| GO:006053721 | Breast | DCIS | muscle tissue development | 50/1390 | 403/18723 | 2.39e-04 | 3.74e-03 | 50 |
| GO:00147062 | Breast | DCIS | striated muscle tissue development | 46/1390 | 384/18723 | 8.88e-04 | 1.01e-02 | 46 |
| GO:000854422 | Breast | DCIS | epidermis development | 40/1390 | 324/18723 | 1.05e-03 | 1.16e-02 | 40 |
| GO:000991322 | Breast | DCIS | epidermal cell differentiation | 27/1390 | 202/18723 | 2.11e-03 | 1.97e-02 | 27 |
| GO:00302162 | Breast | DCIS | keratinocyte differentiation | 20/1390 | 139/18723 | 3.24e-03 | 2.74e-02 | 20 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0520520 | Prostate | BPH | Proteoglycans in cancer | 72/1718 | 205/8465 | 4.16e-07 | 4.10e-06 | 2.54e-06 | 72 |
| hsa0401010 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
| hsa05132113 | Prostate | BPH | Salmonella infection | 99/1718 | 249/8465 | 7.26e-13 | 1.50e-11 | 9.27e-12 | 99 |
| hsa0451018 | Prostate | BPH | Focal adhesion | 85/1718 | 203/8465 | 1.17e-12 | 2.28e-11 | 1.41e-11 | 85 |
| hsa05205110 | Prostate | BPH | Proteoglycans in cancer | 72/1718 | 205/8465 | 4.16e-07 | 4.10e-06 | 2.54e-06 | 72 |
| hsa0401013 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
| hsa0513229 | Prostate | Tumor | Salmonella infection | 98/1791 | 249/8465 | 2.55e-11 | 5.28e-10 | 3.27e-10 | 98 |
| hsa0451025 | Prostate | Tumor | Focal adhesion | 84/1791 | 203/8465 | 3.44e-11 | 6.69e-10 | 4.15e-10 | 84 |
| hsa0520525 | Prostate | Tumor | Proteoglycans in cancer | 73/1791 | 205/8465 | 1.01e-06 | 9.82e-06 | 6.09e-06 | 73 |
| hsa0401022 | Prostate | Tumor | MAPK signaling pathway | 87/1791 | 302/8465 | 8.46e-04 | 3.94e-03 | 2.45e-03 | 87 |
| hsa0513237 | Prostate | Tumor | Salmonella infection | 98/1791 | 249/8465 | 2.55e-11 | 5.28e-10 | 3.27e-10 | 98 |
| hsa0451035 | Prostate | Tumor | Focal adhesion | 84/1791 | 203/8465 | 3.44e-11 | 6.69e-10 | 4.15e-10 | 84 |
| hsa0520535 | Prostate | Tumor | Proteoglycans in cancer | 73/1791 | 205/8465 | 1.01e-06 | 9.82e-06 | 6.09e-06 | 73 |
| hsa0401032 | Prostate | Tumor | MAPK signaling pathway | 87/1791 | 302/8465 | 8.46e-04 | 3.94e-03 | 2.45e-03 | 87 |
| hsa0513212 | Stomach | GC | Salmonella infection | 42/708 | 249/8465 | 7.57e-06 | 1.05e-04 | 7.41e-05 | 42 |
| hsa0513213 | Stomach | GC | Salmonella infection | 42/708 | 249/8465 | 7.57e-06 | 1.05e-04 | 7.41e-05 | 42 |
| hsa0513221 | Stomach | CAG with IM | Salmonella infection | 42/640 | 249/8465 | 5.52e-07 | 9.75e-06 | 6.84e-06 | 42 |
| hsa0513231 | Stomach | CAG with IM | Salmonella infection | 42/640 | 249/8465 | 5.52e-07 | 9.75e-06 | 6.84e-06 | 42 |
| hsa0513241 | Stomach | CSG | Salmonella infection | 42/633 | 249/8465 | 4.10e-07 | 6.82e-06 | 4.91e-06 | 42 |
| hsa0513251 | Stomach | CSG | Salmonella infection | 42/633 | 249/8465 | 4.10e-07 | 6.82e-06 | 4.91e-06 | 42 |
| Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FLNB | SNV | Missense_Mutation | novel | c.1132G>A | p.Asp378Asn | p.D378N | O75369 | protein_coding | deleterious(0.03) | probably_damaging(0.924) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| FLNB | SNV | Missense_Mutation | novel | c.1797N>T | p.Gln599His | p.Q599H | O75369 | protein_coding | deleterious(0.01) | possibly_damaging(0.726) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| FLNB | SNV | Missense_Mutation | c.1202N>A | p.Thr401Asn | p.T401N | O75369 | protein_coding | deleterious(0.02) | benign(0.03) | TCGA-A7-A26J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| FLNB | SNV | Missense_Mutation | rs144158201 | c.2035N>T | p.Pro679Ser | p.P679S | O75369 | protein_coding | tolerated(0.15) | benign(0.314) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| FLNB | SNV | Missense_Mutation | rs768998920 | c.163N>C | p.Glu55Gln | p.E55Q | O75369 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| FLNB | SNV | Missense_Mutation | c.2166G>C | p.Trp722Cys | p.W722C | O75369 | protein_coding | tolerated(0.1) | probably_damaging(0.997) | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| FLNB | SNV | Missense_Mutation | rs80356520 | c.4912C>G | p.Arg1638Gly | p.R1638G | O75369 | protein_coding | deleterious(0.02) | possibly_damaging(0.726) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| FLNB | SNV | Missense_Mutation | novel | c.6208N>T | p.Val2070Leu | p.V2070L | O75369 | protein_coding | deleterious(0.01) | possibly_damaging(0.626) | TCGA-AR-A24M-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| FLNB | SNV | Missense_Mutation | novel | c.3056N>T | p.Thr1019Ile | p.T1019I | O75369 | protein_coding | deleterious(0.02) | possibly_damaging(0.673) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| FLNB | SNV | Missense_Mutation | rs142229998 | c.7462N>A | p.Gly2488Ser | p.G2488S | O75369 | protein_coding | deleterious(0.02) | probably_damaging(0.926) | TCGA-BH-A208-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |